Understanding the impact of high-risk human papillomavirus on oropharyngeal squamous cell carcinomas in Taiwan: A retrospective cohort study

Guadalupe Lorenzatti Hiles[1,2☯], Kai-Ping Chang[3,4☯*], Emily L. Bellile[5], Chun-I Wang[6], Wei-Chen Yen[3], Christine M. Goudsmit[1,2], Hannah L. Briggs[1,2], Trey B. Thomas[1,2,7], Lila Peters[1,2], Macy A. Afsari[1,2], Lisa M. Pinatti[1,2,8], Anna C. Morris[1,2,9], Nadine Jawad[1,2,10], Thomas E. Carey[1,2‡*], Heather M. Walline[1,2‡*].

[1]Division of Head and Neck Surgery, Department of Otolaryngology, University of Michigan Medical School, Ann Arbor, USA.

[2]University of Michigan Rogel Cancer Center, Ann Arbor, USA.

[3]Department of Otolaryngology-Head & Neck Surgery, Chang Gung Memorial Hospital (Linkou Medical Center), Taoyuan, Taiwan.

[4]College of Medicine, Chang Gung University, Taoyuan, Taiwan.

[5]Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, USA.

[6]Radiation Biology Research Center, Institute for Radiological Research, Chang Gung University and Chang Gung Memorial Hospital, Taoyuan, Taiwan.

[7]Present address: School of Public Health, University of Michigan, Ann Arbor, USA.

[8]Cancer Biology Program, Rackham Graduate School, University of Michigan, Ann Arbor, USA.

[9]Present address: Department of Health Policy and Management, Milken Institute School of Public Health, George Washington University, Washington DC, USA.

[10]Present address: Stanford University School of Medicine, Stanford, USA.

☯These authors contributed equally to this work.

‡These authors are joint senior authors on this work.

*E-mail: dr.kpchang@gmail.com (K-PC),

careyte@med.umich.edu (TEC),

hwalline@med.umich.edu (HMW)

Short Title:

High-risk HPV and OPSCC in Taiwan

Author ORCID identifiers:

G. Lorenzatti Hiles: 0000-0002-8423-3279

K.-P. Chang: 0000-0003-1777-9578

E. L. Bellile: 0000-0003-4350-4658

H. L. Briggs: 0000-0003-0686-4523

T.B. Thomas: 0000-0002-5730-5417

M. A. Afsari: 0000-0003-3784-3848

L. M. Pinatti: 0000-0002-4864-5698

N. Jawad: 0000-0003-0325-5319

T. E. Carey: 0000-0002-5202-7518

H. M. Walline: 0000-0003-3790-5738

Manuscript Section or Category: Global Health.

ABSTRACT

Background

In North America and Western Europe, human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma (OPSCC) has increased dramatically over the past 40 years, whereas HPV-negative OPSCC, typically associated with alcohol and tobacco as etiological factors, has declined. In Taiwan, the OPSCC rate is increasing; however, there is limited understanding of the role of HPV, as tobacco, alcohol, and betel quid use are still very prominent. Here we investigated the involvement of HPV and its prognostic implications for OPSCC in Taiwan.

Methods and findings

We studied a retrospective cohort of 541 OPSCCs undergoing care between 1998 and 2016 at the Chang Gung Memorial Hospital-Linkou, Taiwan. Clinical and risk exposure data were retrieved from hospital charts. Most cases were males (94%) and had concomitant (87%) exposure to alcohol (51%), tobacco (83%), and betel quid (65%). Formalin-fixed, paraffin-embedded tissue sections were immunostained for p16, a surrogate for active HPV, and DNA was tested for HPV detection and genotyping by Multiplex PCR-MassArray. Tumors with p16 and/or HPV DNA positivity were identified as HPV-positive. HPV status was assigned to 528 tumors. The prevalence of HPV-positive OPSCC was 28.4% (150/528), with a strong correlation between p16 and HPV DNA results ($F < 0.0001$). We observed an incremental trend for HPV-positive OPSCC over 18 years. HPV16 alone was found in 76.9%, and HPV58 in 7.5% tumors.

Among males more tumors were HPV-negative than positive, but among the 34 females more tumors were HPV-positive (62% vs. 38%, $p < 0.0001$), more commonly from the tonsils ($p < 0.01$), and less prone to use tobacco, alcohol, and betel quid ($p < 0.0001$).

For all patients, HPV-positive OPSCC was associated with higher age at diagnosis (55.5 vs. 52.7 years, $p = 0.004$), and lower T-stage ($p = 0.02$). HPV-positivity in OPSCC tumors was an independent predictor of better overall survival (OS) (hazard ratio [HR] 0.57 [95% CI 0.41-0.80],

p = 0.0009), and disease-free survival (DFS) (HR 0.53 [95% CI 0.40-0.72], p < 0.0001) in multivariable estimations for up to 5-year post-diagnosis. Alcohol consumption was strongly associated with higher risk of recurrence and death (OS: HR 2.02 [95% CI 1.52-2.68], p < 0.0001; DFS: HR 1.70 [95% CI 1.31-2.21], p < 0.0001). No predictive associations were found for smoke or betel quid. Kaplan-Meier's OS and DFS were longer in HPV-positive cases (p < 0.0001), but this advantage decreased for alcohol users (p < 0.0001). Lastly, HPV-positive OPSCC had the best outcomes in non-drinkers, non-smokers, and non-betel quid chewers, but the prognostic benefit of HPV persisted in the presence of these risk factors.

Conclusions

Consistent with the increasing role of HPV on OPSCC globally, HPV is an important etiological factor in more than one-fourth of OPSCC cases from Chang Gung Hospital. Like in Western countries, HPV provides considerable independent survival benefits to OPSCC, but the added prognostic value is reduced by exposure to the risk factors, alcohol, smoking, and betel quid. There is a need to consider HPV as an etiologic factor in treatment and in cancer-prevention policies in Taiwan.

AUTHOR SUMMARY

Why was this study done?

- Oropharyngeal squamous cell carcinoma (OPSCC) caused by human papillomavirus (HPV) has been increasing with epidemic proportions in North America and West Europe during the last 40 years. Socioeconomic changes have propelled the advance of this disease, and transformation from the classic etiology of OPSCC, alcohol, and tobacco, to HPV.
- Contrarily, in Taiwan, OPSCC has been drastically increasing due to persistent heavy consumption of alcohol, smoking, and betel quid chewing, limiting the understanding of HPV contribution to OPSCC. This study investigated the role of HPV in OPSCC in Taiwan.

What did the researchers do and find?

- We conducted a comprehensive retrospective cohort study for 541 OPSCC cases diagnosed between 1998-2016 at the Chang Gung Memorial Hospital-Linkou, Taiwan.
- We found that OPSCCs mostly occurred in men (94%) and risk factors, including use of alcohol, tobacco, and betel quid was high (87%).
- Active HPV was present in 28.4% of the cases, 25% of tumors from males and 62% of tumors from females were HPV-positive. HPV16 was the most prevalent genotype (76.9%), followed by HPV58 (7.5%).
- Most of the HPV-positive OPSCCs originated in the tonsils, and females were less likely to abuse alcohol, tobacco, and betel quid than the males.
- Furthermore, outcome analysis showed that for the whole cohort, HPV positivity was associated with significantly better OPSCC survival. Alcohol was a strong negative prognostic factor. The robust prognostic benefit of HPV persisted in the presence of all other risk factors.

What do these findings mean?

- HPV is an important emerging etiologic factor of OPSCC in Taiwan, and an independent predictor for better prognosis.
- The strong association of HPV with OPSCC over a period of 18 years suggests that societal behavioral changes are occurring; and, that there is a potential for benefit from interventions to improve treatment and prevent HPV-positive OPSCC in Taiwan and South-East Asia.

INTRODUCTION

The occurrence of oropharyngeal squamous cell carcinoma (OPSCC) is rapidly increasing in North America and Western Europe, accounting for approximately 100,000 new cases worldwide each year (1-3). In particular, the incidence of OPSCC has been dramatically rising since 1973,

at the point of surpassing 5% annual increment in the United States in 2000 (2, 4, 5). OPSCC has been traditionally associated with tobacco use and excessive alcohol consumption as primary risk factors (6-17). However, recent behavioral changes in Western countries have promoted a marked drop in the prevalence of these major risk factors (7, 13, 18, 19). In contrast, high-risk human papillomavirus (hrHPV), HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 73, has become the leading etiologic factor of OPSCC (2, 20-28).

Since the World Health Organization recognized the causative link between 15 hrHPV genotypes and the onset of OPSCC in 2007 (29), hrHPV has been increasingly accepted as the principal etiological cause of this malignancy (2, 20, 22, 24, 30-34). HPV-driven OPSCC is markedly on the rise (2, 4, 10, 22-24, 35-37). In the United States, the estimated proportion of positive cases has gone from 20% in 1990 to >70%, where hrHPV now represents the most common cause of OPSCC (2, 7, 27, 36, 38). Countries in Western Europe have observed similar trends (7, 13, 36, 37, 39-41). Interestingly, these changes have been accompanied by an increment in the survival rates for OPSCC (36, 42, 43). HPV-positive patients have a significantly better response to treatment (radiation therapy and chemotherapy as well as surgery) and a more favorable prognosis than those diagnosed with HPV-negative OPSCC (23, 25, 27, 28, 35, 42, 44-50).

Despite these observations, recent studies from Taiwan suggest that its high OPSCC rates continue to increase predominantly due to heavy alcohol drinking, cigarette smoking and betel quid chewing as etiologic factors (9, 51-54). The strong influence of these risk habits has limited the search for a viral etiology in this population. There have been a few studies indicating that hrHPV is an emerging risk for head and neck cancer in South-East Asia, with a prevalence of HPV-positive OPSCC reported to be absent or present in 12.6% (55-57) to 34% (57-62) of OPSCCs. In this study, we conducted a retrospective cohort analysis to interrogate the prevalence and significance of HPV-driven OPSCC in tissue samples collected from a single site in Taiwan over a period of 18 years. We evaluated the association between clinical characteristics

and traditional risk factors (alcohol, smoking, and betel quid) with HPV-associated OPSCC in Taiwan. HPV results were correlated with risk factor exposure for outcomes and survival analysis.

METHODS

Case identification and study design

This study was performed on a retrospective cohort of OPSCC cases diagnosed from March 1998 to February 2016 at the Chang Gung Memorial Hospital (CGMH)-Linkou in Taoyuan, Taiwan, as described in Figure 1. Case selection was not a source of bias as we identified OPSCC tumors through hospital electronic and pathology records from all patients that underwent curative-intent therapy at this tertiary healthcare center. Primary tumors were biopsied only or resected by surgery and collected for histopathological diagnosis. All patients with available pathology archived tissue and known clinical records were included in this cohort (Fig.1). In total, 541 OPSCC tumors were retrieved, anonymized, and shipped for HPV and p16 testing at the University of Michigan. Five non-squamous cell carcinoma cases were excluded from the study based on their pathological classification and histopathological re-assessment of the submitted sections.

To analyze the contribution of hrHPV on these OPSCC cases, data on the common risk factors, alcohol consumption, smoking, and betel quid chewing habits were collected. Smoking is the only use of tobacco in Taiwan because betel quid preparations do not contain tobacco and tobacco chewing is an extremely uncommon behavior (9, 63). Demographic information, including patient characteristics (age at diagnosis, and gender), as well as clinical information (stage, tumor site, initial treatment, and outcomes for recurrence, metastasis, and death), were compiled from patient records. Cases were staged at diagnosis according to the seventh edition of the American Joint Cancer Committee (AJCC) (64).



Fig 1. Flow diagram of cases included in the Taiwan retrospective cohort and study design. [1]Results missing due to absent slide or tissue core, or major artifacts that prevented evaluation. [2]Results missing due to absent DNA or invalid test. OPSCC, oropharyngeal squamous cell carcinoma; HPV, human papillomavirus; FFPE, formalin-fixed, paraffin-embedded; IHC, immunohistochemical staining; PCR-MA, multiplex PCR-MassArray.

174 **Ethics statement.** This retrospective study was approved by the Institutional Review

Boards of the University of Michigan Medical School and the Chang Gung Memorial Hospital and conducted in compliance with the ethical guidelines of the World Medical Association's Declaration of Helsinki (1964, amended in 2013) and local regulations. Additional patient consent was not required by the institutional review boards as this OPSCC cohort comprised secondary use of tissue specimens with unidentified chart data. The procedures described in this manuscript followed the reporting standards for human subject research of the EQUATOR Network, which are detailed in the STROBE report for this study (S1 Checklist).

HPV interrogation

All OPSCC tumors were evaluated for the presence of HPV by two complementary methods: p16 testing and detection of HPV DNA types (65-67) (Fig. 1). Results from each determination were blinded to the investigators to avoid bias. Tumors with either p16 and/or HPV DNA positivity were defined as HPV-positive.

Detection and genotyping of HPV DNA by Multiplex PCR-MassArray (PCR-MA). DNA was isolated from tissue curls of formalin-fixed, paraffin-embedded (FFPE) tumor specimens. Two to seven 10-µm FFPE sections were combined in each extraction with AllPrep DNA/RNA FFPE Kit (Catalog No. 80234, QIAGEN, Germantown, MD, US), according the manufacturer's recommendations. DNA was eluted in DNase-free water and stored at -20 °C until testing. DNA concentration was measured by a Qubit 2.0 Fluorometer (Catalog No. Q32866, Invitrogen-Thermo Fisher Scientific Inc., Waltham, MA, US) and the Qubit dsDNA HS Assay Kit (Catalog No. Q32851, Invitrogen-Thermo Fisher Scientific Inc., US).

Samples were examined for the presence of HPV DNA and genotyped by PCR-MA analysis, a very sensitive, high-throughput method based on competitive PCR and probe-specific single-base extension coupled with MALDI-TOF mass spectrometry (65-67). The PCR-MA assay is designed to detect 15 high-risk (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 73), and 2 low-risk (HPV 6 and 11) HPV types, and a possible high-risk subtype (HPV90), as

previously described by our laboratory (65-67). Reactions were prepared with 20 ng of DNA and carried out in quadruplicates in an area physically separated from DNA isolation. Tests were run using a Mass Array 384-format System (Agena Bioscience Inc., San Diego, CA, US). Specimen acceptability was determined using human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) DNA control.

p16 testing by immunohistological analysis. FFPE tissue sections (4-µm) were used for p16 immunostaining with a specific antibody against Protein Cyclin-dependent kinase inhibitor 2A (CDKN2A), also known as p16INK4a, to characterize the presence of active HPV (68). The immunohistochemical (IHC) staining was carried out manually using the clinically validated CINtec-p16 (E6H4) antibody (pre-diluted, Ref. No. 725-4713, Ventana Medical Systems Inc., Tucson, AZ, USA) as stated by the supplier's protocol. The CINtec-p16 primary antibody was incubated for 1 hour at room temperature followed by washing and appropriate horseradish peroxidase-labeled secondary antibody for 30 minutes at room temperature. All slides were stained with 3,3′-diaminobenzidine for 1-5 minutes, followed by hematoxylin counterstain.

p16 IHC was examined for each slide at 200x and 400x magnification according to the 2018 recommendations of the College of American Pathologists (68). p16 expression was scored as positive if ≥ 70% of the tumor cells exhibited strong and diffuse nuclear and cytoplasmic p16 immunoreactivity (S1 Fig).

Statistical analysis

Two-sided Fisher's exact test (*F*) was used to analyze the relationship between p16 and HPV DNA results. The association between HPV prevalence and study year was evaluated by two-sided simple linear regression and Spearman rank correlation (ρ). Data for HPV status, alcohol consumption, cigarette smoking, betel quid chewing, age, gender, T-stage, N-stage, disease site, initial treatment, and clinical outcomes were collected as covariates. Standard descriptive statistics were performed for each covariate collected. Differences in the distribution of covariates

by HPV status were tested by two-sided t-test (continuous measures) or Pearson's chi-squared test (χ^2) (categorical/binary). Time-to-event outcomes were defined beginning from date of pathology diagnosis to death from any cause (Overall Survival), or from date of pathology diagnosis to date of first recurrence or death (Disease-Free Survival); subjects alive with no event were censored at date of last follow-up. The Kaplan-Meier method and log-rank tests were used to estimate survival probabilities and plot survival distributions. Cox proportional hazard models and hazard ratio (HR) estimations for time up to 5 years post-diagnosis were performed to test relative hazards between groups in the whole cohort and in subsets stratified by HPV status or other risk factors (alcohol consumption, cigarette smoking and/or betel quid chewing). Cases with no HPV status data (p16 or HPV DNA), N = 13, were excluded, leaving 528 cases eligible for Chi-squared and survival calculations. Tests were also performed to examine the variates and survival distributions by gender. Statistical analyses were conducted in SAS v9.4 (SAS Institute Inc., Cary, NC, US) using R v3.6.1 (RStudio, Boston, MA, US) for graph generation, or GraphPad Prism v8.3.0 (GraphPad Software, San Diego, CA, US). Statistical tests were performed using 95% confidence intervals and a 5% significance level.

RESULTS

HPV status and clinical characteristics

A total of 546 OPSCC cases were obtained from an unbiased retrospective chart review of individuals treated with standard of care therapy in Taiwan, from March 1998 to February 2016. Among these cases, five were not OPSCC according to the pathology records and slide review; these were excluded as they did not fulfill our inclusion criteria. Therefore, the final study cohort included 541 OPSCC cases (Fig. 1, S1 Table).

The presence of HPV in FFPE tumor sections of oropharyngeal cancer was assessed by IHC staining for p16, a surrogate marker for active HPV (68) (Fig. 1, S1 Fig., S1 Table). HPV genotypes were identified by PCR-MA (65-67) using tumor genomic DNA (Fig. 1, S1 Table). Of

the 541 OPSCC tumors tested, p16 was positive in 115 (21.3%), negative in 355 (65.6%), and 71 (13.1%) could not be scored. HPV detection and genotyping showed that 134 (24.8%) tumors were HPV-positive, 379 (68.4%) HPV-negative, and 37 (6.8%) had insufficient DNA (failed to amplify the GAPDH control) (Fig. 1, S1 Table, S2 Table). Of these, HPV16 was found alone in 103 (76.9%) and HPV58 was the second most frequently found in 10 (7.5%) tumors. HPV66, HPV59, HPV45, HPV39, HPV34, HPV31, HPV18, and HPV6 were also found in 13 (9.7%) individual tumors. HPV16 was also present together with other HPV genotypes (HPV6, HPV18, HPV35, HPV58, or HPV59) in 8 (6.0%) tumors (Table 1; S1 Table). These results indicate, that aside from low-risk HPV6, there are diverse oncogenic HPV genotypes in Taiwan OPSCCs.

Table 1. HPV genotypes frequency.

HPV Genotype	Frequency	Percent	Cumulative Frequency	Cumulative Percent
HPV16	103	76.87	103	76.87
HPV58	10	7.46	113	84.33
HPV35	3	2.24	116	86.57
HPV18	2	1.49	118	88.06
HPV31	2	1.49	120	89.55
HPV45	2	1.49	122	91.04
HPV59	2	1.49	124	92.53
HPV66	1	0.75	125	93.28
HPV6	1	0.75	126	94.03
HPV16 HPV58	2	1.49	128	95.52
HPV16 HPV18	2	1.49	130	97.01
HPV16 HPV6	2	1.49	132	98.50
HPV16 HPV35	1	0.75	133	99.25
HPV16 HPV59	1	0.75	134	100

Altogether, p16 overexpression was strongly correlated with HPV status in OPSCC, as the concordance between p16 and HPV DNA testing was 94.9% (423 out of 446, $F < 0.0001$, S2 Table). Therefore, for this study, we defined HPV positivity as either positive by p16 or HPV DNA test. Thus, we had 528 OPSCC tumors with HPV status (positive or negative) called. HPV status (p16 and HPV DNA) data were not obtained for thirteen cases and were not included in the analysis (Fig. 1, S1 Table, S2 Table). The prevalence of HPV-positive OPSCC in the whole cohort

was 28.4% (150 out of 528) (Fig. 1). Interestingly, when we examined the yearly occurrence of HPV-positive OPSCC, we found that there was a trend for an increase over the 18 years of study, but it failed to reach statistical significance (Fig. 2; S3 Table). We also observed a clear increment in the number of HPV-negative cases that drive the growing incidence of OPSCC rates in Taiwan, thereby obscuring the gradual rise of HPV-positive OPSCCs. Nevertheless, our results demonstrate an increasing role of oncogenic HPV and its causal role as an etiologic factor of OPSCC in Taiwan.



Fig. 2. Yearly HPV occurrence among OPSCC cases. The graph shows the correlation between the total frequency of HPV-positive (HPV+) and HPV-negative (HPV-) OPSCC cases, and the study years (see S3 Table). The association was evaluated in the Taiwan cohort from March 1998 to February 2016 (N = 528) by Spearman's coefficient (ρ) and linear regression (R^2) (HPV-: ρ = 0.6953, p = 0.0014; R^2 = 0.5201, p = 0.0007. HPV+ ρ = 0.4093, p = 0.0917; R^2 = 0.1952, p = 0.0664).

Next, we assessed the demographic and clinical features of the whole cohort, as listed in Table 2. In our study, males represented 94% (507 out of 541) of all cases, and the average age at tumor diagnosis was 53.5 years old. Over half of the tumors, 58% (315 out of 541), were biopsied or resected from the tonsils, followed by 24% (132 out of 541) from the soft palate, 17% (90 out of 541) from the base of the tongue, and 1% (4 out of 541) from non-specified locations in the oropharynx. The large majority of the cohort had a history of previous exposure to known

Table 2. Demographic and clinical characteristics.

		Whole cohort N = 541	Stratified by HPV N = 528		
			HPV- N = 378	HPV+ N = 150	
Variable		N (%)	N (%)	N (%)	*p*-Value
Age [Mean (std)]	**Years**	**53.5 (10.4)**	**52.7 (10.1)**	**55.5 (10.6)**	**0.004**
Gender	**Male**	**507 (94%)**	**365 (97%)**	**129 (86%)**	**<0.0001**
	Female	**34 (6%)**	**13 (3%)**	**21 (14%)**	
Stage	0	3 (<1%)	2 (<1%)	1 (<1%)	0.60
	1	27 (5%)	20 (5%)	7 (5%)	
	2	67 (12%)	47 (12%)	19 (13%)	
	3	84 (16%)	61 (16%)	16 (11%)	
	4	359 (66%)	248 (66%)	106 (71%)	
T-stage	**0**	**2 (<1%)**	**1 (<1%)**	**1 (<1%)**	**0.02**
	1	**64 (12%)**	**47 (12%)**	**15 (10%)**	
	2	**186 (34%)**	**117 (31%)**	**68 (46%)**	
	3	**107 (20%)**	**74 (20%)**	**27 (18%)**	
	4	**181 (34%)**	**139 (37%)**	**38 (26%)**	
N-stage	0	169 (31%)	122 (32%)	41 (28%)	0.22
	1	77 (14%)	59 (16%)	16 (11%)	
	2	246 (46%)	165 (44%)	77 (52%)	
	3	48 (9%)	32 (8%)	15 (10%)	
Disease Site	**Soft Palate**	**132 (24%)**	**111 (29%)**	**19 (13%)**	**<0.0001**
	Tongue Base	**90 (17%)**	**67 (18%)**	**22 (15%)**	
	Tonsil	**315 (58%)**	**196 (52%)**	**109 (73%)**	
	Oropharynx other	**4 (1%)**	**4 (1%)**	**0 (0%)**	
Initial Treatment	Chemoradiation	403 (75%)	279 (75%)	114 (77%)	0.29
	Radiation	89 (17%)	59 (16%)	27 (18%)	
	Surgery	43 (8%)	35 (9%)	8 (5%)	
Risk Factors					
Alcohol	**Yes**	**278 (51%)**	**213 (56%)**	**56 (37%)**	**<0.0001**
Smoke	**Yes**	**448 (83%)**	**339 (90%)**	**97 (65%)**	**<0.0001**
Betel Quid	**Yes**	**349 (65%)**	**285 (75%)**	**53 (35%)**	**<0.0001**
Alcohol and/or Smoke and/or Betel Quid	**Yes**	**468 (87%)**	**351 (93%)**	**105 (70%)**	**<0.0001**
Outcomes					
Death		310	237	65	
recurrence		99	82	12	
neck recurrence		82	67	13	
Metastasis		55	39	13	

p-values derived from t-test (continuous measures) or Chi-square test (categorical) by HPV status, missing values were excluded. TNM classification, according to the 7th AJCC staging edition: "T" (T classification), "N" (N classification), and "Stage" (overall stage). Because all cases were presented with no metastasis (M0), there is no heading for M. The individual variables "Alcohol", "Smoke, and "Betel Quid" were not adjusted for exposure to the other two risk factors.

risk factors: 51% (278 out of 541) drank alcohol, 83% (448 out of 541) smoked, and 65% (349 out of 541) chewed betel quid (Table 2, S4 Table). Most prominently, 87% (468 out of 541) of these individuals concomitantly used alcohol, tobacco, and/or betel quid. Never-smokers, never-drinkers, and never-betel quid chewers accounted for a small 13% (73 out 541) of the cases (S4 Table). Because of the high density of risk factors, and their combined exposure, we were unable to separate their individual effects. Therefore, only 1% (7 out of 541) of the Taiwan cohort was exposed to alcohol without smoking or betel quid chewing, 11% (60 out of 541) solely smoked, and 1% (5 out of 541) only consumed betel quid (S4 Table).

We then examined the clinical determinants of HPV status (Table 2). When compared to HPV-negative cases, HPV-positive individuals had a slightly higher average age at diagnosis (55.5 vs. 52.7 years, $p = 0.004$), and slightly lower T-stage (majority of T2 cases vs. T4, $p = 0.02$). The HPV-positive tumors were also most frequently located in the tonsils (73% vs. 52%, $p < 0.0001$); and presented lower exposure to all the risk factors including alcohol (37% vs. 56%, $p < 0.0001$), smoking (65% vs. 90%, $p < 0.0001$), and betel quid (35% vs. 75%, $p < 0.0001$) (Table 2, S4 Table). Although the number of females was far lower, representing only 6% (34 out of 541) of the cases (Table 2), they showed pronounced differences with males (S5 Table). The majority, 62% (21 out of 34) of tumors from females, but a minority, 25% (129 out of 507) of tumors from males, were HPV-positive ($p < 0.0001$). The proportion of tonsil tumors was also higher in females than in males (85% vs. 56%, $p = 0.01$), and were more likely to be N3/N4 ($p = 0.03$) (AJCC 7th edition). The females had lower exposure to alcohol (18% vs. 54%, $p < 0.0001$), smoking (21% vs. 87%, $p < 0.0001$), and betel quid (12% vs. 68%, $p < 0.0001$); and thus, were more likely be never users of these high risk carcinogens. Females also tended to be older at diagnosis (mean: 58.7 years vs. 53.1 years, $p = 0.002$). There was also a slightly better prognosis for the female group (OS: log-rank $p = 0.05$; DFS: log-rank $p = 0.07$) (S2 Fig), but given the small group size (N = 34), this observation should be carefully interpreted.

The role of HPV status and associated-risk factors on OPSCC outcome

First, we determined if HPV status had survival benefits on OPSCC by multivariable and Kaplan-Meier analysis (Fig. 3, S6 Table). Compared to HPV-negative cases, patients with HPV-positive OPSCC had significantly higher overall survival (HR 0.57, 95% CI 0.41 to 0.80, *p*= 0.0009; log-



Fig 3. HPV-positive OPSCC is associated with increased survival time. (A-B) Up to 5-year overall survival (OS) and disease-free survival (DFS) prognostic outcomes of HPV in Taiwan OPSCC. (A) Table includes the multivariable hazard probabilities analyzed using Cox survival models and hazard ratio (HR) estimations, visualized by forest plots. The complete analysis is found in S6 Table. (B) Kaplan-Meier survival analysis. Plots represent the results for up to 5-year OS (left) and DFS (right) comparison between HPV-negative (HPV-) and HPV-positive (HPV+) groups. Log-rank analysis was used to compare the survival distributions (log-rank *p*-values are in the plots). HPV-, HPV-negative; HPV+, HPV-positive.

rank $p < 0.0001$) and disease-free survival (HR 0.53, 95% CI 0.40 to 0.72, $p < 0.0001$; log-rank $p < 0.0001$) for up to 5-year post-diagnosis, suggesting that HPV-positivity was an independent predictor for better prognosis.

Similar analyses also revealed that consumption of alcohol was a strong negative prognostic factor for both up to 5-year overall survival (HR 2.02, 95% CI 1.52 to 2.68, $p < 0.0001$; log-rank $p < 0.0001$) and disease-free survival (HR 1.70, 95% CI 1.31 to 2.21, $p < 0.0001$; log-


A
Outcome
Variable
HR (95% CI)
p-Value
OS
Alcohol
2.02 (1.52-2.68)
<0.0001
Smoke
0.72 (0.48-1.08)
0.11
Betel Quid
0.87 (0.63-1.19)
0.38
DFS
Alcohol
1.70 (1.31-2.21)
<0.0001
Smoke
0.79 (0.54-1.14)
0.20
Betel Quid
0.86 (0.64-1.16)
0.33
0.1
1
10
HR (95% CI)
B
Whole cohort
OS Probability
Alcohol=No
Alcohol=Yes
p<0.0001
No. at risk:
Alcohol=
No 263 209 183 150 111 85
Yes 278 199 151 117 100 88
Years
Whole cohort
DFS Probability
Alcohol=No
Alcohol=Yes
p<0.0001
No. at risk:
Alcohol=
No 263 139 95 69 48 34
Yes 278 138 103 82 73 46
C
Whole cohort
OS Probability
Smoke=No
Smoke=Yes
p=0.24
No. at risk:
Smoke=
No 93 68 61 52 47 36
Yes 448 340 273 215 164 137
Whole cohort
DFS Probability
Smoke=No
Smoke=Yes
p=0.40
No. at risk:
Smoke=
No 93 51 38 31 27 18
Yes 448 226 160 120 94 62
D
Whole cohort
OS Probability
Betel quid=No
Betel quid=Yes
p=0.05
No. at risk:
Betel quid=
No 192 149 124 104 86 69
Yes 349 259 210 163 125 104
Whole cohort
DFS Probability
Betel quid=No
Betel quid=Yes
p=0.05
No. at risk:
Betel quid=
No 192 106 73 60 51 37
Yes 349 171 125 91 70 43

317

Fig. 4. Alcohol is associated with reduced OPSCC survival time. (A-D) Prognostic outcomes of alcohol, smoking, and betel quid within the whole cohort. We analyzed up to 5-year overall survival (OS) and disease-free survival (DFS) outcomes for high-risk habits. (A) Table includes the multivariable hazard probabilities analyzed using Cox survival models and hazard ratio (HR) estimations, visualized by forest plots. The complete analysis is found in S6 Table. (B-D) Kaplan-Meier survival analysis. Plots represent the results for up to 5-year OS (left) and DFS (right) comparison between alcohol (B), smoke (C), and betel quid (D) groups. Log-rank analysis was used to compare the survival distributions (log-rank *p*-values are in the plots).

rank $p < 0.0001$) (Fig. 4, S6 Table). Surprisingly, smoking, and betel quid chewing had only discrete predictive effects (Fig. 4, S6 Table).

Additional multivariable survival analysis and Kaplan-Meier estimations for alcohol, smoking, and betel quid groups, controlled for HPV status, were also performed (Fig. 5, S3 Fig., S7 Table). For alcohol users, the independent observations were also preserved in the HPV-positive and HPV-negative groups, where HPV was associated with longer OPSCC survival time (Survival by alcohol within HPV groups, OS: HPV-positive log-rank $p = 0.0007$, HPV-negative long rank $p < 0.0001$ – DFS: HPV-positive log-rank $p = 0.02$, HPV-negative long rank $p = 0.0005$). Most importantly, our data demonstrate that the prognostic benefit of HPV positivity persists in the presence of risk factors, alcohol, and tobacco and betel quid (DFS by HPV within risk groups: alcohol yes $p = 0.008$, alcohol no $p = 0.007$; tobacco+betel quid yes $p = 0.0006$, tobacco+betel quid no $p = 0.01$) (S4 Fig., S8 Table). Thus, indicating that HPV-positive OPSCC had the best outcomes in non-drinkers, non-smokers, and non-betel quid chewers. In sum, our study shows that hrHPV has a causative role but also provides a significant prognostic benefit for OPSCC in Taiwan.


A
Outcome
Variable
Risk Group
HR (95% CI)
p-Value
OS
Alcohol
HPV+
1.69 (0.95-3.03)
0.08
HPV-
1.72 (1.28-2.31)
0.0004
Smoke
HPV+
0.99 (0.53-1.87)
0.98
HPV-
1.00 (0.56-1.79)
0.99
Betel Quid
HPV+
0.93 (0.52-1.64)
0.79
HPV-
0.87 (0.63-1.21)
0.41
DFS
Alcohol
HPV+
1.33 (0.79-2.23)
0.29
HPV-
1.49 (1.14-1.95)
0.003
Smoke
HPV+
0.78 (0.78-1.20)
0.26
HPV-
0.80 (0.54-1.17)
0.25
Betel Quid
HPV+
1.01 (0.60-1.72)
0.96
HPV-
0.85 (0.64-1.14)
0.29
0.1
1
10
HR (95% CI)
B
HPV+
OS Probability
Alcohol=No
Alcohol=Yes
p=0.0007
Years
No. at risk:
Alcohol=
No 94 83 77 66 50 40
Yes 56 46 37 29 26 25
HPV-
OS Probability
Alcohol=No
Alcohol=Yes
p<0.0001
Years
No. at risk:
Alcohol=
No 165 123 103 81 60 44
Yes 213 146 108 83 69 59
C
HPV+
DFS Probability
Alcohol=No
Alcohol=Yes
p=0.02
Years
No. at risk:
Alcohol=
No 94 55 44 37 28 21
Yes 56 36 30 23 22 15
HPV-
DFS Probability
Alcohol=No
Alcohol=Yes
p=0.0005
Years
No. at risk:
Alcohol=
No 165 82 50 31 20 13
Yes 213 96 68 54 47 27

Fig. 5. In alcohol users, HPV is associated with improved OPSCC survival time. (A-C) Prognostic outcomes of alcohol, smoking, and betel quid within HPV risk groups. We analyzed up to 5-year overall survival (OS) and disease-free survival (DFS) outcomes. (A) Table includes the multivariable hazard probabilities analyzed using Cox survival models and hazard ratio (HR) estimations, visualized by forest plots. (B-C) Kaplan-Meier survival analysis. Plots represent the results for up to 5-year OS (B) and DFS (C) comparison between HPV groups stratified by alcohol groups. Log-rank analysis was used to compare the survival distributions (log-rank *p*-values are in the plots). The complete analysis is found in S7 Table and S3 Fig. HPV-, HPV-negative; HPV+, HPV-positive.

DISCUSSION

In Western countries, the prevalence of HPV-driven OPSCC has been rising drastically in the last 4 decades to become one of most widespread malignancies (2, 4, 10, 22-24, 35-37). Those affected by OPSCC suffer great losses due to aggressive treatment, morbidity, and death (20, 28, 35, 36, 42, 43, 45, 47-50, 69, 70). Still, the extent of this disease and its public health impact are not well understood outside North America and Western Europe. In this retrospective cohort study, we performed a comprehensive investigation of the impact of HPV-driven OPSCC in Taiwan from 1998 to 2016. We found that active HPV was present in 28.4% of the tumors, with a trend for incremental occurrence over time. HPV16 was the most prevalent genotype (76.9%), followed by HPV58 (7.5%), and other diverse genotypes. HPV-positive OPSCCs occurred in higher proportion in females and presented with different clinical features than their HPV-negative counterparts, including reduced engagement in risk behaviors such as alcohol drinking, cigarette smoking, and betel quid chewing. Additional outcome analysis of the entire cohort showed that HPV-positivity was associated with a notably higher survival rate. Surprisingly, only alcohol, but not smoking or betel quid, were strongly associated with a worse prognosis. The strong prognostic benefit of HPV remained present but reduced in the presence of the associated risk factors alcohol, smoking, and betel quid.

Many studies have demonstrated an increment of HPV-driven OPSCC in numerous countries, showing considerable geographical variability in the proportion of cases over time (36, 71, 72). Recent estimates calculate the worldwide prevalence of HPV-positive OPSCC between

18% and 35.6% (24, 73). Reports from the United States, demonstrate a marked incremental variability over the years, from 20% by 1990 to over 70% of OPSCCs being currently caused by hrHPV (2, 7, 27, 36, 38). Studies at the University of Michigan alone have shown a prevalence of 82.3% (27). Reports from other developed countries and Western Europe, such as the United Kingdom and Finland, have observed a similar increment in prevalence of HPV-positive OPSCC during the last decades (7, 13, 36, 37, 39-41, 72). Differently, in South-East Asia, recent studies have shown a slower trend for these increments, with the proportion of HPV-positive OPSCC varying from 0% to 34% in different populations (9, 20, 57-62). In neighboring Hong Kong, hrHPV has been found in 20.8% of tumors (59). Likewise, a limited number of studies from Taiwan, suggested that hrHPV is a rising etiological factor in head and neck cancer, including OPSCC (55-57). Particularly, Chien et al. demonstrated that in the early 2000s, 12.6% of the squamous cell tonsillar carcinomas were positive for hrHPV in Taiwan (57). Here, our study indicates that the proportion of HPV-positive OPSCCs in the cosmopolitan Taiwanese population presented an incremental trend from 1998 to 2016. With an overall prevalence of 28.4%, our results suggest similar proportions in Taiwan than those observed in 1990 in the US (38). Given this global historical data, we anticipate that Taiwan will also have a significant marked increment going forward in the rates of HPV-related OPSCC. Although the observed prevalence is three-fold lower in Taiwan compared with Western countries, this is higher than that reported for the US Asian population (12.8%) (46). The slower incremental occurrence of HPV-positive OPSCC over 18 years that we have shown, as well as differences in prevalence in comparison to other populations, suggest a different distribution of etiological factors, such as lifestyle choices leading to higher smoking and alcohol drinking and different sexual behavior in Taiwan. Our high concordance between HPV-DNA and p16 surrogate marker positivity indicates that HPV was transcriptionally active in the tested specimens and a likely etiological driver of oropharyngeal carcinogenesis.

Of important note, our study sheds light on the causal association between HPV genotypes and OPSCC in Taiwan. It is well-recognized that certain high-risk viral genotypes are carcinogenic and highly associated with the development of OPSCC (2, 36), most especially HPV16 (3, 11, 29, 42, 73, 74). In line with the predominant worldwide prevalence of HPV16 in OPSCC, this has also been identified in the majority of cases from Southern China (59), and previous reports in tonsillar squamous cell carcinomas in Taiwan (57). Coincidentally, in our current study, HPV16 accounted for the vast majority (76.9%) of HPV-positive OPSCCs, followed by HPV58 in 7.5% of cases. Apart from HPV16 and HPV58, other oncogenic hrHPV genotypes were infrequent, and HPV18, which often causes cancer in the Western world, was only present in a very small proportion of the specimens (1.5% alone and 1.5% in combination with HPV16). Interestingly, our previous work has shown similar low proportion of HPV18-positive OPSCCs in the United States (65). In addition, it has been reported that oral HPV infections in betel nut chewers and smokers, are mainly caused by HPV16. Still, HPV58 has been found at a low percentage in Northern Taiwan, especially in patients with the highest exposure to traditional habits that increase cancer risk (56). Likewise, a literature search for the genotype prevalence of other HPV-related cancers within East Asia and Taiwan, showed that in Northern China HPV16 is dominant in cervical carcinomas (75, 76). This prevalence decreases in the Southern regions of the country (20, 77), to become similar to the observed occurrence of other important genotypes in Taiwan, HPV52 and HPV58 (78). Although HPV16 has been found in over 80% of cervical cancers in Asia, it has been reported in only 50% of the cervical cancers in Taiwan (79). In this population, HPV58 is the second or the third most common genotype found in cervical malignancies (~20%, together with HPV18) and cervical HPV infections, but it is rare in other parts of the world (80-83). HPV52, usually found in cervical cancers in East Asia (59, 84, 85) was not detected in our Taiwanese cohort. This particular distribution of HPV genotypes suggests tissue or geographic specificity for HPV16 and HPV58 in Taiwan, where HPV is becoming an increasingly important etiologic factor of OPSCC.

As part of our study, we also analyzed the clinical determinants of HPV positivity in OPSCC. This malignancy is considered one of the leading causes of cancer death in Asian and Taiwan males (9, 55). Curiously, even when most of the cases in our cohort were males (94%), females had most commonly HPV-positive tumors and presented reduced alcohol, smoking, or betel quid habits. There was also a trend for slightly better prognosis within the female group (S2 Fig). This indicates that OPSCC is a disease affecting the Taiwanese women, while more research is necessary to address their specific clinical management. Moreover, HPV-positive tumors were associated with a slightly higher age at diagnosis (mean = 55.5 years) than HPV-negatives. This represents another particularity since hrHPV has been historically associated with the onset of OPSCCs in younger, middle-aged individuals (23, 35, 39, 44, 59, 86), even in Taiwan, where the average age at diagnosis has been reported between 40 and 50 years of age (55). Despite this belief, new studies have contradicted these trends by demonstrating that the highest HPV prevalence occurs in patients above 55 and even 70 years of age (19, 87, 88). This suggests a similar changing epidemiology in Taiwan, with a possible shift of sexual onset at a later age, reduced number of sexual partners in life, or reinfection later in life. Even when our data diverge from previous reports, these agree with studies from Southern China and Western countries indicating a significant correlation between HPV status and earlier primary tumor stage (T-stage) (3, 59). However, our results demonstrate a higher T-stage within the entire cohort (T3-4 instead of T1-2), although the most common T class among HPV+ tumors was T2 (46%) but among HPV- tumors the most common T-class was T4 (37%). N-stage did not present a significant association with HPV status. These HPV-positive tumors were associated with the tonsils as their primary location, denoting site-specificity, as also indicated in previous observations from Taiwan (55). Thus, our results indicate that HPV-driven OPSCC is a clinically unique disease with distinctive features to the Taiwanese patients.

Furthermore, the carcinogenic effect of the risk factors alcohol, smoking, and betel quid has been very well characterized. These are considered the main etiological agents of HPV-

negative OPSCC (6-13, 15-17). It has been proposed that the observed increasing rates of OPSCC in East Asia and Taiwan are related to the excessive and extensive use of alcohol, smoking, and betel quid (which does not contain tobacco) (9, 51-54, 63). Previous studies in Taiwan report that exposure to these agents represents a high risk for developing, primarily intraoral cancer (9, 57). For this reason, it was not surprising to observe that above two thirds of the OPSCC cases in our study tested negative for HPV and had a prominent smoking (83%), betel quid chewing (65%) or alcohol drinking (51%) history (Table 2, S4 Table). Earlier findings also showed a similar proportion of alcohol drinkers within the Taiwanese male population (9). Interestingly, in our cohort, 87% of the individuals with OPSCC used these chemical carcinogens in combination. Only 1% of the cohort consumed alcohol or betel quid alone, and 11% only smoked (S4 Table). Although these historically causative risk factors are still very prominent in Taiwan, we observed that only alcohol consumption is a significant determinant of worse prognosis. This is surprising, as tobacco smoking has been found to be the most important predictor of unfavorable outcome and risk factor in OPSCC, as patients with mutant p53 have a reduced capacity to repair DNA (3, 25, 27, 44, 90). The reasons for the dwarfed effect of smoking and betel quid as negative drivers remain elusive, but they may reside in the high proportion of smokers in the cohort (83%) or individuals with a complex combination of risk factors, as shown in S4 Table. This makes it impossible to separate the individual effects of the carcinogens, alcohol, tobacco, and betel quid, which could have additive effects on DNA damage and potentiate the negative impact of alcohol. Alternatively, alcohol could also represent a surrogate for lack of social support or socioeconomic disadvantage. Additionally, our findings reveal that HPV-positive tumors were less exposed to these three risk factors, which correlates with previous reports indicating that individuals with HPV-positive OPSCCs are more likely to be never or former smokers, or drinkers (25, 57, 59, 89, 90). Nonetheless, these are common risk factors for HPV-positive OPSCC, and in Western countries, 10-30% of OPSCC tumors occur in individuals that smoke or drink (27, 91). In this study, we observed a transformation from cancer that is derived

from only smoking, betel quid, and alcohol influence, to an increasing trend of HPV-positive cases. The strong association of HPV with better outcome has been widely reported (23, 25, 27, 28, 35, 42, 44-50). Our results, showing that HPV-positive OPSCCs have a strikingly better prognosis, agree with these and previous work from South-East Asia and Taiwan (57, 59). Additional evidence showed that in our Taiwan cohort, even when having poorer outcomes, drinkers, smokers, and betel quid users benefited from the simultaneous presence of HPV, displaying higher OPSCC survival rates than those HPV-negative. This demonstrates that even when having HPV was enough to cause OPSCCs, interactions exist with drinking, smoking, and betel quid habits. Similar interactions have been seen before, especially for smoking or tobacco and HPV (27, 90). These results may have a substantial impact on the clinical management of OPSCC patients in Taiwan and their risk stratification. In consequence, HPV-positive individuals could benefit from the secession of alcohol, smoking, or betel quid habits and therapy de-escalation, as it is currently tested in diverse hospital settings to reduce toxicity and post-treatment morbidity (13, 49, 50, 59, 92, 93).

To our knowledge, this is the first comprehensive study analyzing the impact of HPV-driven OPSCC in Taiwan. Our approach of matching actual HPV status and prevalence data to clinical features, risk behavior exposure, and clinical outcomes represents a distinctive strength of our study, adding to our understanding of an under-represented ethnic group in Western epidemiological studies. Also, double p16-HPV DNA testing provided clinical relevance to the findings, as the concordance of the results was very high. Because p16 as a surrogate marker for HPV-driven OPSCCs can account for more than 5% false positives (10, 94, 95), we did not rely solely on this test and performed DNA testing for HPV. Our study also suffers from limitations. Cases from a single center, the Chang Gung Memorial Hospital at Linkou, in Taiwan, were included in the study. Even when lacking nationwide reach, this is the largest medical center in the country, providing a valid representation of the Taiwanese population. An additional limitation is represented by the lack of both p16 and HPV-DNA results for all the specimens, as several

were missing or had insufficient amount of tissue available for analysis (see Fig. 1, S1 Table). The retrospective nature of our study also presented challenges to this work. We could not evaluate the impact of therapy because changes to treatment strategies occurred over time, and we were unable to follow changes in sexual behaviors that could perhaps help explain the occurrence of HPV in Taiwan. Data on risk factors were limited, as we could not retrieve the exact amounts and type of alcohol, cigarettes, or betel quid consumed, nor information on previous infections with hrHPV. For the same reason, disease specific survival times could not be calculated. The AJCC TNM staging system changed to include HPV status in 2017 (96); however, our cases were classified at diagnosis following previous guidance, and staging changes were not reflected in the reported N-status.

After all, future research should incorporate efforts to further characterize HPV-driven OPSCC in Taiwan. Since our cohort included a limited number of females, future studies aiming at clarifying the implication of this disease in women, who also suffer from HPV-driven cervical and genital cancers, are needed. Importantly, studies related to the collection of specific epidemiological data will be relevant to guide new public health policies. Since oral hrHPV infections precede the development of OPSCC, research on the natural history of this disease, including the prevalence of HPV genotypes, will help strengthen the current HPV vaccination efforts. The HPV vaccine was recently introduced in Taiwan in 2018, only targeting prepubescent girls. Still, our studies reflect that boys will also benefit from vaccination, as it has the potential to halt the expansion of HPV-positive OPSCC and other cancers (40, 56, 59). Since HPV vaccination uptake is presumably low, new prospective studies have the potential to shed light on the risk of OPSCC within the vaccinated population and have broad public health implications for control measures. Lastly, multicenter, nationwide studies will provide an understanding of the variables leading to HPV oncogenesis in this population, improving risk definition, outcome prediction, and patient stratification. All these are necessary to provide patients with adequate care based on their HPV status. Additional investigations into the molecular mechanism of HPV-induced OPSCC

are also required to address the risk of recurrence and progression in Taiwan. Based on risk evaluation, HPV-positive OPSCC patients may be candidates for therapy de-intensification. Tailored interventions should also be designed based on longitudinal investigations of the interaction between HPV and risk behaviors drinking, smoking, and chewing betel quid.

In conclusion, our large retrospective cohort study provides empirical evidence on the impact of hrHPV on OPSCCs in Taiwan. We found that HPV is active and, most likely, an increasing etiological factor in Taiwanese individuals with OPSCC. These observations may represent continuous behavioral changes in Taiwan. HPV positivity is associated with significantly better outcomes. Involvement in risk habits, alcohol, cigarette, and betel quid use was still widespread, but the substantial prognostic benefit of HPV remained present. Thus, this consistent trend reflects the need for policies and sustained public health interventions aiming to improve the management and prevention of HPV-driven OPSCC in Taiwan.

ACKNOWLEDGMENTS

We would like to thank the patients who generously contributed to the study, and all the members of the Cancer Center, Chang Gung Memorial Hospital, for their invaluable help.

AUTHOR CONTRIBUTIONS

Conceptualization: Thomas E. Carey, Kai-Ping Chang, Heather M. Walline, Guadalupe Lorenzatti Hiles, Emily L. Bellile.

Data Curation: Guadalupe Lorenzatti Hiles, Emily L. Bellile, Chun-I Wang, Wei-Chen Yen, Lisa M. Pinatti, Heather M. Walline.

Formal Analysis: Guadalupe Lorenzatti Hiles, Emily L. Bellile, Heather M. Walline.

Funding Acquisition: Guadalupe Lorenzatti Hiles, Kai-Ping Chang, Thomas E. Carey, Heather M. Walline.

Investigation: Guadalupe Lorenzatti Hiles, Chun-I Wang, Wei-Chen Yen, Christine M. Goudsmit, Hannah L. Briggs, Trey B. Thomas, Lila Peters, Macy A. Afsari, Anna C. Morris, Nadine Jawad, Heather M. Walline.

Project Administration: Thomas E. Carey, Kai-Ping Chang, Heather M. Walline, Guadalupe Lorenzatti Hiles, Christine M. Goudsmit.

Resources: Kai-Ping Chang, Thomas E. Carey, Heather M. Walline.

Supervision: Kai-Ping Chang, Thomas E. Carey, Heather M. Walline.

Validation: Guadalupe Lorenzatti Hiles, Emily L. Bellile, Hannah L. Briggs, Macy A. Afsari, Heather M. Walline.

Visualization: Guadalupe Lorenzatti Hiles, Emily L. Bellile, Macy A. Afsari.

Writing – Original Draft Preparation: Guadalupe Lorenzatti Hiles.

Writing – Review & Editing: Guadalupe Lorenzatti Hiles, Kai-Ping Chang, Emily L. Bellile, Chun-I Wang, Wei-Chen Yen, Christine M. Goudsmit, Hannah L. Briggs, Trey B. Thomas, Lila Peters, Macy A. Afsari, Lisa M. Pinatti, Anna C. Morris, Nadine Jawad, Thomas E. Carey, Heather M. Walline.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. Epub 2018/09/12. doi: 10.3322/caac.21492. PubMed PMID: 30207593.
2. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944-56. doi: 10.1056/NEJMoa065497. PubMed PMID: 17494927.
3. Elrefaey S, Massaro MA, Chiocca S, Chiesa F, Ansarin M. HPV in oropharyngeal cancer: the basics to know in clinical practice. Acta Otorhinolaryngol Ital. 2014;34(5):299-309. PubMed PMID: 25709145; PubMed Central PMCID: PMCPMC4299160.
4. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer. 2005;103(9):1843-9. doi: 10.1002/cncr.20998. PubMed PMID: 15772957.
5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. Epub 2019/01/08. doi: 10.3322/caac.21551. PubMed PMID: 30620402.
6. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988;48(11):3282-7. PubMed PMID: 3365707.
7. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head

Neck Oncol. 2010;2:15. Epub 2010/06/29. doi: 10.1186/1758-3284-2-15. PubMed PMID: 20587061; PubMed Central PMCID: PMCPMC2908081.

8. Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2009;18(2):541-50. Epub 2009/02/03. doi: 10.1158/1055-9965.EPI-08-0347. PubMed PMID: 19190158; PubMed Central PMCID: PMCPMC3051410.

9. Ho PS, Ko YC, Yang YH, Shieh TY, Tsai CC. The incidence of oropharyngeal cancer in Taiwan: an endemic betel quid chewing area. J Oral Pathol Med. 2002;31(4):213-9. doi: 10.1034/j.1600-0714.2002.310404.x. PubMed PMID: 12076324.

10. Nauta IH, Rietbergen MM, van Bokhoven AAJD, Bloemena E, Lissenberg-Witte BI, Heideman DAM, et al. Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing. Ann Oncol. 2018;29(5):1273-9. doi: 10.1093/annonc/mdy060. PubMed PMID: 29438466.

11. Sturgis EM, Ang KK. The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms? J Natl Compr Canc Netw. 2011;9(6):665-73. doi: 10.6004/jnccn.2011.0055. PubMed PMID: 21636538.

12. Talamini R, Vaccarella S, Barbone F, Tavani A, La Vecchia C, Herrero R, et al. Oral hygiene, dentition, sexual habits and risk of oral cancer. Br J Cancer. 2000;83(9):1238-42. doi: 10.1054/bjoc.2000.1398. PubMed PMID: 11027440; PubMed Central PMCID: PMCPMC2363583.

13. Westra WH. The morphologic profile of HPV-related head and neck squamous carcinoma: implications for diagnosis, prognosis, and clinical management. Head Neck Pathol. 2012;6 Suppl 1:S48-54. Epub 2012/07/03. doi: 10.1007/s12105-012-0371-6. PubMed PMID: 22782223; PubMed Central PMCID: PMCPMC3394160.

14. Znaor A, Brennan P, Gajalakshmi V, Mathew A, Shanta V, Varghese C, et al. Independent and combined effects of tobacco smoking, chewing and alcohol drinking on the risk of oral, pharyngeal and esophageal cancers in Indian men. Int J Cancer. 2003;105(5):681-6. doi: 10.1002/ijc.11114. PubMed PMID: 12740918.

15. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, World Health Organization., International Agency for Research on Cancer. Betel-quid and areca-nut chewing and some areca-nut-derived nitrosamines. Lyon, France Geneva: IARC Press ; Distributed by IARC Press and the World Health Organization Marketing and Dissemination; 2004. x, 334 p. p.

16. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans., International Agency for Research on Cancer., National Cancer Institute (U.S.). Alcohol drinking. Lyon, France: World Health Organization, International Agency for Research on Cancer; 1988. 416 p. p.

17. IARC Working Group on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, International Agency for Research on Cancer. Tobacco habits other than smoking, betel-quid and areca-nut chewing, and some related nitrosamines. Lyon, France: International Agency for Research on Cancer; 1985. 291 pages, 4 pages of plates p.

18. Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA. 2014;311(2):183-92. doi: 10.1001/jama.2013.284692. PubMed PMID: 24399557.

19. Zumsteg ZS, Cook-Wiens G, Yoshida E, Shiao SL, Lee NY, Mita A, et al. Incidence of Oropharyngeal Cancer Among Elderly Patients in the United States. JAMA Oncol. 2016;2(12):1617-23. doi: 10.1001/jamaoncol.2016.1804. PubMed PMID: 27415639.

20. Allen CT, Lewis JS, El-Mofty SK, Haughey BH, Nussenbaum B. Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope. 2010;120(9):1756-72. doi: 10.1002/lary.20936. PubMed PMID: 20669304.

21. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol. 2006;24(17):2606-11. doi: 10.1200/JCO.2006.06.1291. PubMed PMID: 16763272; PubMed Central PMCID: PMCPMC4696042.

22. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709-20. doi: 10.1093/jnci/92.9.709. PubMed PMID: 10793107.

23. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100(6):407-20. Epub 2008/03/11. doi: 10.1093/jnci/djn025. PubMed PMID: 18334711.
24. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2015;33(29):3235-42. Epub 2015/09/08. doi: 10.1200/JCO.2015.61.6995. PubMed PMID: 26351338; PubMed Central PMCID: PMCPMC4979086.
25. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008;26(19):3128-37. Epub 2008/05/12. doi: 10.1200/JCO.2007.12.7662. PubMed PMID: 18474878; PubMed Central PMCID: PMCPMC2744895.
26. Licitra L, Bossi P, Locati LD. A multidisciplinary approach to squamous cell carcinomas of the head and neck: what is new? Curr Opin Oncol. 2006;18(3):253-7. doi: 10.1097/01.cco.0000219254.53091.35. PubMed PMID: 16552237.
27. Maxwell JH, Kumar B, Feng FY, Worden FP, Lee JS, Eisbruch A, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res. 2010;16(4):1226-35. Epub 2010/02/09. doi: 10.1158/1078-0432.CCR-09-2350. PubMed PMID: 20145161; PubMed Central PMCID: PMCPMC2822887.
28. Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JM, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol. 2008;26(19):3138-46. Epub 2008/05/12. doi: 10.1200/JCO.2007.12.7597. PubMed PMID: 18474879; PubMed Central PMCID: PMCPMC2742158.
29. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans., International Agency for Research on Cancer. Human papillomaviruses. Lyon, France Geneva, Switzerland: World Health Organization. Distributed by WHO Press; 2007. viii, 670 p. p.
30. Begum S, Cao D, Gillison M, Zahurak M, Westra WH. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res. 2005;11(16):5694-9. doi: 10.1158/1078-0432.CCR-05-0587. PubMed PMID: 16115905.
31. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol. 2009;10(4):321-2. doi: 10.1016/s1470-2045(09)70096-8. PubMed PMID: 19350698.
32. Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001;344(15):1125-31. doi: 10.1056/NEJM200104123441503. PubMed PMID: 11297703.
33. Rampias T, Sasaki C, Weinberger P, Psyrri A. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst. 2009;101(6):412-23. Epub 2009/03/10. doi: 10.1093/jnci/djp017. PubMed PMID: 19276448.
34. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157-60. Epub 2011/07/28. doi: 10.1126/science.1208130. PubMed PMID: 21798893; PubMed Central PMCID: PMCPMC3415217.
35. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26(4):612-9. doi: 10.1200/JCO.2007.14.1713. PubMed PMID: 18235120.
36. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294-301. Epub 2011/10/03. doi: 10.1200/JCO.2011.36.4596. PubMed PMID: 21969503; PubMed Central PMCID: PMCPMC3221528.
37. Ernster JA, Sciotto CG, O'Brien MM, Finch JL, Robinson LJ, Willson T, et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope. 2007;117(12):2115-28. doi: 10.1097/MLG.0b013e31813e5fbb. PubMed PMID: 17891052.
38. Stein AP, Saha S, Yu M, Kimple RJ, Lambert PF. Prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in the United States across time. Chem Res Toxicol. 2014;27(4):462-9. Epub 2014/04/02. doi: 10.1021/tx500034c. PubMed PMID: 24641254; PubMed Central PMCID: PMCPMC4002059.

39. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31(36):4550-9. Epub 2013/11/18. doi: 10.1200/JCO.2013.50.3870. PubMed PMID: 24248688; PubMed Central PMCID: PMCPMC3865341.
40. Gooi Z, Chan JY, Fakhry C. The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer. Laryngoscope. 2016;126(4):894-900. Epub 2016/02/04. doi: 10.1002/lary.25767. PubMed PMID: 26845348.
41. Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer. 2006;119(11):2620-3. doi: 10.1002/ijc.22177. PubMed PMID: 16991119.
42. Boscolo-Rizzo P, Pawlita M, Holzinger D. From HPV-positive towards HPV-driven oropharyngeal squamous cell carcinomas. Cancer Treat Rev. 2016;42:24-9. Epub 2015/10/31. doi: 10.1016/j.ctrv.2015.10.009. PubMed PMID: 26547133.
43. Gatta G, Botta L, Sánchez MJ, Anderson LA, Pierannunzio D, Licitra L, et al. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. Eur J Cancer. 2015;51(15):2130-43. Epub 2015/09/26. doi: 10.1016/j.ejca.2015.07.043. PubMed PMID: 26421817.
44. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24-35. Epub 2010/06/07. doi: 10.1056/NEJMoa0912217. PubMed PMID: 20530316; PubMed Central PMCID: PMCPMC2943767.
45. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261-9. Epub 2008/02/12. doi: 10.1093/jnci/djn011. PubMed PMID: 18270337.
46. Fakhry C, Westra WH, Wang SJ, van Zante A, Zhang Y, Rettig E, et al. The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer. Cancer. 2017;123(9):1566-75. Epub 2017/02/27. doi: 10.1002/cncr.30353. PubMed PMID: 28241096; PubMed Central PMCID: PMCPMC5788020.
47. Haughey BH, Hinni ML, Salassa JR, Hayden RE, Grant DG, Rich JT, et al. Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck. 2011;33(12):1683-94. Epub 2011/01/31. doi: 10.1002/hed.21669. PubMed PMID: 21284056.
48. Horne ZD, Glaser SM, Vargo JA, Ferris RL, Balasubramani GK, Clump DA, et al. Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas. Cancer. 2016;122(13):2021-30. Epub 2016/04/25. doi: 10.1002/cncr.30021. PubMed PMID: 27111669.
49. Quon H, Cohen MA, Montone KT, Ziober AF, Wang LP, Weinstein GS, et al. Transoral robotic surgery and adjuvant therapy for oropharyngeal carcinomas and the influence of p16 INK4a on treatment outcomes. Laryngoscope. 2013;123(3):635-40. Epub 2013/02/01. doi: 10.1002/lary.22172. PubMed PMID: 22588642.
50. Rietbergen MM, Brakenhoff RH, Bloemena E, Witte BI, Snijders PJ, Heideman DA, et al. Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials. Ann Oncol. 2013;24(11):2740-5. Epub 2013/08/14. doi: 10.1093/annonc/mdt319. PubMed PMID: 23946330.
51. Chuang SL, Su WW, Chen SL, Yen AM, Wang CP, Fann JC, et al. Population-based screening program for reducing oral cancer mortality in 2,334,299 Taiwanese cigarette smokers and/or betel quid chewers. Cancer. 2017;123(9):1597-609. Epub 2017/01/05. doi: 10.1002/cncr.30517. PubMed PMID: 28055109.
52. Hsu KY, Tsai YF, Huang CC, Yeh WL, Chang KP, Lin CC, et al. Tobacco-Smoking, Alcohol-Drinking, and Betel-Quid-Chewing Behaviors: Development and Use of a Web-Based Survey System. JMIR Mhealth Uhealth. 2018;6(6):e142. Epub 2018/06/11. doi: 10.2196/mhealth.9783. PubMed PMID: 29891467; PubMed Central PMCID: PMCPMC6018239.
53. Lee YA, Li S, Chen Y, Li Q, Chen CJ, Hsu WL, et al. Tobacco smoking, alcohol drinking, betel quid chewing, and the risk of head and neck cancer in an East Asian population. Head Neck. 2019;41(1):92-102. Epub 2018/12/15. doi: 10.1002/hed.25383. PubMed PMID: 30552826.
54. Shiu MN, Chen TH. Impact of betel quid, tobacco and alcohol on three-stage disease natural history of oral leukoplakia and cancer: implication for prevention of oral cancer. Eur J Cancer Prev. 2004;13(1):39-45. doi: 10.1097/00008469-200402000-00007. PubMed PMID: 15075787.

55. Hwang TZ, Hsiao JR, Tsai CR, Chang JS. Incidence trends of human papillomavirus-related head and neck cancer in Taiwan, 1995-2009. Int J Cancer. 2015;137(2):395-408. Epub 2014/11/24. doi: 10.1002/ijc.29330. PubMed PMID: 25395239.

56. Wang CP, Chen TC, Chen HH, Hsu WL, Chang YL. Prevalence of current oral HPV infection among 100 betel nut chewers or cigarette smokers in Northern Taiwan. J Formos Med Assoc. 2019;118(1 Pt 1):203-8. Epub 2018/04/07. doi: 10.1016/j.jfma.2018.03.013. PubMed PMID: 29636296.

57. Chien CY, Su CY, Fang FM, Huang HY, Chuang HC, Chen CM, et al. Lower prevalence but favorable survival for human papillomavirus-related squamous cell carcinoma of tonsil in Taiwan. Oral Oncol. 2008;44(2):174-9. Epub 2007/04/05. doi: 10.1016/j.oraloncology.2007.01.018. PubMed PMID: 17418614.

58. Huang H, Zhang B, Chen W, Zou SM, Zhang YX, Qiao YL. [Detection of human papillomavirus in oropharyngeal squamous cell carcinoma]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2012;34(6):545-9. doi: 10.3881/j.issn.1000-503X.2012.06.002. PubMed PMID: 23286396.

59. Lam EW, Chan JY, Chan AB, Ng CS, Lo ST, Lam VS, et al. Prevalence, Clinicopathological Characteristics, and Outcome of Human Papillomavirus-Associated Oropharyngeal Cancer in Southern Chinese Patients. Cancer Epidemiol Biomarkers Prev. 2016;25(1):165-73. Epub 2015/11/24. doi: 10.1158/1055-9965.EPI-15-0869. PubMed PMID: 26604268.

60. Li W, Tran N, Lee SC, O'Brien CJ, Tse GM, Scolyer RA, et al. New evidence for geographic variation in the role of human papillomavirus in tonsillar carcinogenesis. Pathology. 2007;39(2):217-22. doi: 10.1080/00313020701230823. PubMed PMID: 17454751.

61. Maruyama H, Yasui T, Ishikawa-Fujiwara T, Morii E, Yamamoto Y, Yoshii T, et al. Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population. Cancer Sci. 2014;105(4):409-17. Epub 2014/03/30. doi: 10.1111/cas.12369. PubMed PMID: 24521534; PubMed Central PMCID: PMCPMC4317800.

62. No JH, Sung MW, Hah JH, Choi SH, Lee MC, Kim HS, et al. Prevalence and prognostic value of human papillomavirus genotypes in tonsillar squamous cell carcinoma: a Korean multicenter study. Cancer. 2015;121(4):535-44. Epub 2014/10/03. doi: 10.1002/cncr.29086. PubMed PMID: 25283642.

63. Ko YC, Chiang TA, Chang SJ, Hsieh SF. Prevalence of betel quid chewing habit in Taiwan and related sociodemographic factors. J Oral Pathol Med. 1992;21(6):261-4. doi: 10.1111/j.1600-0714.1992.tb01007.x. PubMed PMID: 1501158.

64. Edge SB, American Joint Committee on Cancer., American Cancer Society. AJCC cancer staging handbook : from the AJCC cancer staging manual. 7th ed. New York: Springer; 2010. xix, 718 p. p.

65. Walline HM, Komarck C, McHugh JB, Byrd SA, Spector ME, Hauff SJ, et al. High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods. JAMA Otolaryngol Head Neck Surg. 2013;139(12):1320-7. doi: 10.1001/jamaoto.2013.5460. PubMed PMID: 24177760; PubMed Central PMCID: PMCPMC4049419.

66. Walline HM, Carey TE, Goudsmit CM, Bellile EL, D'Souza G, Peterson LA, et al. High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res. 2017;15(2):179-88. Epub 2016/11/29. doi: 10.1158/1541-7786.MCR-16-0255. PubMed PMID: 27899422; PubMed Central PMCID: PMCPMC5290187.

67. Walline HM, Goudsmit CM, McHugh JB, Tang AL, Owen JH, Teh BT, et al. Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck. 2017;39(5):840-52. Epub 2017/02/25. doi: 10.1002/hed.24729. PubMed PMID: 28236344; PubMed Central PMCID: PMCPMC5392184.

68. Lewis JS, Beadle B, Bishop JA, Chernock RD, Colasacco C, Lacchetti C, et al. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. Arch Pathol Lab Med. 2018;142(5):559-97. Epub 2017/12/18. doi: 10.5858/arpa.2017-0286-CP. PubMed PMID: 29251996.

69. Moore EJ, Olsen SM, Laborde RR, García JJ, Walsh FJ, Price DL, et al. Long-term functional and oncologic results of transoral robotic surgery for oropharyngeal squamous cell carcinoma. Mayo Clin Proc. 2012;87(3):219-25. doi: 10.1016/j.mayocp.2011.10.007. PubMed PMID: 22386176; PubMed Central PMCID: PMCPMC3538408.

70. Yeh DH, Tam S, Fung K, MacNeil SD, Yoo J, Winquist E, et al. Transoral robotic surgery vs. radiotherapy for management of oropharyngeal squamous cell carcinoma - A systematic review of the literature. Eur J Surg Oncol. 2015;41(12):1603-14. Epub 2015/09/26. doi: 10.1016/j.ejso.2015.09.007. PubMed PMID: 26461255.

71. Li W, Thompson CH, O'Brien CJ, McNeil EB, Scolyer RA, Cossart YE, et al. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer. 2003;106(4):553-8. doi: 10.1002/ijc.11261. PubMed PMID: 12845651.
72. Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagué X, Laporte L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014;15(12):1319-31. Epub 2014/10/16. doi: 10.1016/S1470-2045(14)70471-1. PubMed PMID: 25439690.
73. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467-75. doi: 10.1158/1055-9965.EPI-04-0551. PubMed PMID: 15734974.
74. Amit M, Ilana K, Avraham SP, Binenbaum Y, Bachar G, Billan S, et al. Trends in human papillomavirus-related oropharyngeal cancer in Israel. Head Neck. 2016;38 Suppl 1:E274-8. Epub 2015/06/24. doi: 10.1002/hed.23985. PubMed PMID: 25545260.
75. Dai M, Bao YP, Li N, Clifford GM, Vaccarella S, Snijders PJ, et al. Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. Br J Cancer. 2006;95(1):96-101. Epub 2006/06/13. doi: 10.1038/sj.bjc.6603208. PubMed PMID: 16773069; PubMed Central PMCID: PMCPMC2360486.
76. Li LK, Dai M, Clifford GM, Yao WQ, Arslan A, Li N, et al. Human papillomavirus infection in Shenyang City, People's Republic of China: A population-based study. Br J Cancer. 2006;95(11):1593-7. Epub 2006/10/31. doi: 10.1038/sj.bjc.6603450. PubMed PMID: 17088908; PubMed Central PMCID: PMCPMC2360733.
77. Wu RF, Dai M, Qiao YL, Clifford GM, Liu ZH, Arslan A, et al. Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation. Int J Cancer. 2007;121(6):1306-11. doi: 10.1002/ijc.22726. PubMed PMID: 17417776.
78. Lin H, Ma YY, Moh JS, Ou YC, Shen SY, ChangChien CC. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan. Gynecol Oncol. 2006;101(1):40-5. Epub 2005/10/26. doi: 10.1016/j.ygyno.2005.09.028. PubMed PMID: 16256180.
79. Lai CH, Huang HJ, Hsueh S, Chao A, Lin CT, Huang SL, et al. Human papillomavirus genotype in cervical cancer: a population-based study. Int J Cancer. 2007;120(9):1999-2006. doi: 10.1002/ijc.22538. PubMed PMID: 17266033.
80. Chen HC, You SL, Hsieh CY, Schiffman M, Lin CY, Pan MH, et al. Prevalence of genotype-specific human papillomavirus infection and cervical neoplasia in Taiwan: a community-based survey of 10,602 women. Int J Cancer. 2011;128(5):1192-203. Epub 2010/11/16. doi: 10.1002/ijc.25685. PubMed PMID: 20853317.
81. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121(3):621-32. doi: 10.1002/ijc.22527. PubMed PMID: 17405118.
82. Jeng CJ, Phdl, Ko ML, Ling QD, Shen J, Lin HW, et al. Prevalence of cervical human papillomavirus in Taiwanese women. Clin Invest Med. 2005;28(5):261-6. PubMed PMID: 16265998.
83. Wang CH, Garvilles RG, Chen CY. Characterization of human papillomavirus infection in north Taiwan. J Med Virol. 2010;82(8):1416-23. doi: 10.1002/jmv.21812. PubMed PMID: 20572075.
84. Chan PK, Cheung TH, Li WH, Yu MY, Chan MY, Yim SF, et al. Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China. Int J Cancer. 2012;131(3):692-705. Epub 2011/10/05. doi: 10.1002/ijc.26404. PubMed PMID: 21976212.
85. Chan PK, Ho WC, Chan MC, Wong MC, Yeung AC, Chor JS, et al. Meta-analysis on prevalence and attribution of human papillomavirus types 52 and 58 in cervical neoplasia worldwide. PLoS One. 2014;9(9):e107573. Epub 2014/09/17. doi: 10.1371/journal.pone.0107573. PubMed PMID: 25229350; PubMed Central PMCID: PMCPMC4168000.
86. de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2-13. Epub 2017/09/06. doi: 10.1016/j.bpobgyn.2017.08.015. PubMed PMID: 28964706.
87. Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012;307(7):693-703. Epub 2012/01/26. doi: 10.1001/jama.2012.101. PubMed PMID: 22282321; PubMed Central PMCID: PMCPMC5790188.
88. Steinau M, Saraiya M, Goodman MT, Peters ES, Watson M, Cleveland JL, et al. Human papillomavirus prevalence in oropharyngeal cancer before vaccine introduction, United States. Emerg Infect Dis. 2014;20(5):822-8. doi: 10.3201/eid2005.131311. PubMed PMID: 24751181; PubMed Central PMCID: PMCPMC4012803.

845 89. Morbini P, Alberizzi P, Ferrario G, Capello G, De Silvestri A, Pedrazzoli P, et al. The evolving landscape of
846 human papillomavirus-related oropharyngeal squamous cell carcinoma at a single institution in Northern Italy. Acta
847 Otorhinolaryngol Ital. 2019;39(1):9-17. doi: 10.14639/0392-100X-1905. PubMed PMID: 30936574; PubMed Central
848 PMCID: PMCPMC6444161.
849 90. Vawda N, Banerjee RN, Debenham BJ. Impact of Smoking on Outcomes of HPV-related Oropharyngeal
850 Cancer Treated with Primary Radiation or Surgery. Int J Radiat Oncol Biol Phys. 2019;103(5):1125-31. Epub
851 2018/12/01. doi: 10.1016/j.ijrobp.2018.11.046. PubMed PMID: 30513378.
852 91. Smith EM, Rubenstein LM, Haugen TH, Pawlita M, Turek LP. Complex etiology underlies risk and survival in
853 head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor disease. J Oncol.
854 2012;2012:571862. Epub 2012/01/23. doi: 10.1155/2012/571862. PubMed PMID: 22315596; PubMed Central
855 PMCID: PMCPMC3270416.
856 92. Münger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, et al. Mechanisms of human
857 papillomavirus-induced oncogenesis. J Virol. 2004;78(21):11451-60. doi: 10.1128/JVI.78.21.11451-11460.2004.
858 PubMed PMID: 15479788; PubMed Central PMCID: PMCPMC523272.
859 93. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, et al. Characterization of
860 HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014;111(43):15544-
861 9. Epub 2014/10/13. doi: 10.1073/pnas.1416074111. PubMed PMID: 25313082; PubMed Central PMCID:
862 PMCPMC4217452.
863 94. Bussu F, Sali M, Gallus R, Vellone VG, Zannoni GF, Autorino R, et al. HPV infection in squamous cell
864 carcinomas arising from different mucosal sites of the head and neck region. Is p16 immunohistochemistry a reliable
865 surrogate marker? Br J Cancer. 2013;108(5):1157-62. Epub 2013/02/12. doi: 10.1038/bjc.2013.55. PubMed PMID:
866 23403821; PubMed Central PMCID: PMCPMC3619072.
867 95. Rietbergen MM, Snijders PJ, Beekzada D, Braakhuis BJ, Brink A, Heideman DA, et al. Molecular
868 characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas. Int J Cancer.
869 2014;134(10):2366-72. Epub 2013/11/19. doi: 10.1002/ijc.28580. PubMed PMID: 24249631.
870 96. Amin MB, Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual. Eighth edition. ed.
871 Switzerland: Springer; 2017. xvii, 1024 pages p.

SUPPORTING INFORMATION

S1 Checklist. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) report.

S1 Fig. Representative p16 immunostaining for OPSCC tissue sections. Specimens from example p16-negative (P0283) and p16-positive (P0267) tumors are displayed. p16 expression is observed as a brown nuclear and cytoplasmic coloration. Magnification, 200x.

S2 Fig. Kaplan-Meier plots for survival outcomes by gender. Up to 5-year overall survival (OS) and disease-free survival (DFS) outcomes were analyzed within the whole cohort by the Kaplan-Meier method and log-rank test (*p*-values).

S3 Fig. Kaplan-Meier plots for survival outcomes by alcohol, smoking, and betel quid. (A-C) Comparison of prognostic outcomes of alcohol (A), smoke (B), and betel quid (C) between the whole cohort and HPV risk groups. Up to 5-year overall survival (OS, top) and disease-free survival (DFS, bottom) probabilities were analyzed by the Kaplan-Meier method and log-rank test (*p*-values), as displayed for each risk group. HPV-, HPV-negative; HPV+, HPV-positive.

S4 Fig. HPV-positive OPSCC is associated with increased disease-free survival time in the presence of other risk factors. (A-C) Up to 5-year disease-free survival (DFS) prognostic outcome of HPV within alcohol and smoke+quid risk groups. The smoke+quid group comprises OPSCC cases with both betel quid chewing and/or cigarette smoking. The DFS smoke and betel quid variables were not analyzed individually due to low number of events. (A) Table includes the multivariable hazard probabilities analyzed using Cox survival models and hazard ratio (HR) estimations, which were visualized by forest plots. The complete analysis is found in S8 Table. (B-C) Kaplan-Meier survival analysis. Plots represent the DFS probabilities of cases stratified by

HPV status within the alcohol (B) and smoke and/or betel quid groups (C). Left, plots showing cases with alcohol or smoke+quid consumption. Right, plots showing cases without exposition to alcohol or smoke+quid. Log-rank analysis was used to compare the survival distributions (log-rank *p*-values are in the plots). HPV-, HPV-negative; HPV+, HPV-positive.

S1 Table. HPV status and patient data.

S2 Table. p16 vs. HPV DNA results.

S3 Table. Yearly HPV occurrence.

S4 Table. Risk factors exposure characteristics.

S5 Table. Clinical and demographic characteristics by gender.

S6 Table. Multivariable survival analysis of the whole cohort.

S7 Table. Multivariable survival analysis for alcohol, smoking, and quid within HPV Risk Groups, adjusted for T- and N-stage.

S8 Table. Multivariable disease-free survival analysis by HPV within alcohol, and smoking plus betel quid risk groups (controlled for alcohol and smoking plus betel quid).

Data Availability Statement: All relevant data are included in this manuscript and its Supporting Information, excepting sensitive data that could allow the identification of the patients in this study.

The full data set is available upon request to the senior authors and approval of ethical and legal agreements.

Funding: This study was funded by the University of Michigan-Chang Gung Memorial Hospital Pilot Grant (https://www.rogelcancercenter.org and https://www.cgmh.org.tw/en) to K-PC and TEC; the National Cancer Institute at the National Institutes of Health (https://www.cancer.gov), CA194536 to TEC and HMW, and CA194536-S1 to GLH; the Chang Gung Memorial Hospital, CMRPG3H0852, CMRPG3J1251, and CORPG3G0171 to K-PC; the Taiwan Ministry of Science and Technology (https://www.most.gov.tw), MOST 108-2314-B-182A-108-MY3 to K-PC; and, funds from the University of Michigan Undergraduate Research Opportunity Program (https://lsa.umich.edu/urop) to GLH, TEC and HMW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Abbreviations: CGMH, Chang Gung Memorial Hospital; DFS, disease-free survival; EQUATOR, Enhancing the QUAlity and Transparency Of health Research Network; FFPE, formalin-fixed, paraffin-embedded; HPV, human papillomavirus; hrHPV, high-risk human papillomavirus; IHC, immunohistochemical staining; OS, overall survival; OPSCC, oropharyngeal squamous cell carcinoma; PCR-MA, multiplex PCR-MassArray; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology.

SUPPORTING INFORMATION

S1 Fig. Representative p16 immunostaining for OPSCC tissue sections. Specimens from example p16-negative (P0283) and p16-positive (P0267) tumors are displayed. p16 expression is observed as a brown nuclear and cytoplasmic coloration. Magnification, 200x.



S2 Table. p16 vs. HPV DNA results.

p16	HPV DNA			
	. (%)	**0 (%)**	**1 (%)**	**Total (%)**
. **(%)**	13 (2.40)	35 (6.47)	23 (4.25)	71 (13.12)
0 **(%)**	19 (3.51)	324 (59.89)	12 (2.22)	355 (65.62)
1 **(%)**	5 (0.92)	11 (2.03)	99 (18.30)	115 (21.26)
Total **(%)**	37 (6.84)	370 (68.39)	134 (24.77)	541 (100.00)

Keys. p16: (.) Slide missing or not evaluated, (0) negative, (1) positive. HPV DNA: (.) Invalid, (0) negative, (1) positive. The correlation between p16 and HPV DNA results was evaluated by Fisher's exact test ($F < 0.0001$), the corresponding values are in the central dark-gray cells.

S3 Table. Yearly HPV occurrence.

Study Year	HPV-		HPV+		Total	
	Frequency	Percent	Frequency	Percent	Frequency	Percent
1998	14	58.3	10	41.7	24	100
1999	16	76.2	5	23.8	21	100
2000	21	67.7	10	32.3	31	100
2001	8	57.1	6	42.9	14	100
2002	17	65.4	9	34.6	26	100
2003	8	66.7	4	33.3	12	100
2004	16	94.1	1	5.9	17	100
2005	16	84.2	3	15.8	19	100
2006	15	100	0	0	15	100
2007	21	80.8	5	19.2	26	100
2008	30	68.2	14	32.8	44	100
2009	15	53.6	13	46.4	28	100
2010	35	83.3	7	16.7	42	100
2011	34	69.4	15	30.6	49	100
2012	30	65.2	16	34.8	46	100
2013	25	78.1	7	21.9	32	100
2014	31	79.5	8	20.5	39	100
2015	26	60.5	17	39.5	43	100
Total	378	71.6	150	28.4	528	100

Frequency Missing = 13

Study year is March-February of the following year based on the collection dates of specimens.

S4 Table. Risk factors exposure characteristics.

		Whole cohort N = 541	Stratified by HPV N = 528		
			HPV- N = 378	HPV+ N = 150	
Variable		N (%)	N (%)	N (%)	*p*-Value
Risk Factors					
Alcohol	**Yes**	**278 (51%)**	**213 (56%)**	**56 (37%)**	**<0.0001**
Alcohol without Smoke and Betel Quid	**Yes**	**7 (1%)**	**1 (<1%)**	**6 (4%)**	**0.001**
Smoke	**Yes**	**448 (83%)**	**339 (90%)**	**97 (65%)**	**<0.0001**
Smoke without Alcohol and Betel Quid	**Yes**	**60 (11%)**	**33 (9%)**	**27 (18%)**	**0.0009**
Betel Quid	**Yes**	**349 (65%)**	**285 (75%)**	**53 (35%)**	**<0.0001**
Betel Quid without Alcohol and Smoke	**Yes**	**5 (1%)**	**3 (1%)**	**2 (1%)**	**0.5**
Alcohol + Smoke	**Yes**	**463 (86%)**	**348 (92%)**	**103 (69%)**	**<0.0001**
Alcohol + Betel Quid	**Yes**	**408 (75%)**	**318 (74%)**	**78 (52%)**	**<0.0001**
Smoke + Betel Quid	**Yes**	**461 (85%)**	**350 (93%)**	**99 (66%)**	**<0.0001**
Alcohol and/or Smoke and/or Betel Quid	**Yes**	**468 (87%)**	**351 (93%)**	**105 (70%)**	**<0.0001**
(None)	**No**	**73 (13%)**	**27 (7%)**	**45 (30%)**	

p-values derived from Chi-square test (categorical) by HPV status, missing values were excluded. Variables were not adjusted for co-exposure to the other risk factor(s) (colored black). For individual variables "without" "Alcohol," "Smoke," and "Betel Quid" (colored gray), events with combined exposure to either of the other two risk factors, were removed from analysis. "Alcohol + Smoke" may have also used betel quid. "Alcohol + Betel Quid" may have also smoked. "Smoke + Betel Quid" may have also used alcohol.

S5 Table. Clinical and demographic characteristics by gender.

		Whole Cohort N = 541	Male Only N = 507	Female Only N = 34	
Variable		N (%)	N (%)	N (%)	*p*-Value (compared to Males)
Age [Mean (std)]	**Years**	**53.5 (10.4)**	**53.1 (10.1)**	**58.7 (12.1)**	**0.002**
Gender	Male	507 (94%)	507 (100%)		
	Female	34 (6%)		34 (100%)	0.46
Stage	0	3 (<1%)	3 (<1%)	0	
	1	27 (5%)	26 (5%)	1 (3%)	
	2	67 (12%)	63 (12%)	4 (12%)	
	3	84 (16%)	82 (16%)	2 (6%)	
	4	359 (66%)	332 (65%)	27 (79%)	
T-stage	0	2 (<1%)	2 (<1%)	0	0.22
	1	64 (12%)	57 (11%)	7 (21%)	
	2	186 (34%)	171 (34%)	15 (44%)	
	3	107 (20%)	102 (20%)	5 (15%)	
	4	181 (34%)	174 (34%)	7 (21%)	
N-stage	**0**	**169 (31%)**	**164 (32%)**	**5 (15%)**	**0.03**
	1	**77 (14%)**	**75 (15%)**	**2 (6%)**	
	2	**246 (46%)**	**223 (44%)**	**23 (68%)**	
	3	**48 (9%)**	**44 (9%)**	**4 (12%)**	
HPV	**HPV+**	**150 (28%)**	**129 (25%)**	**21 (62%)**	**<0.0001**
	HPV-	**378 (72%)**	**365 (72%)**	**13 (38%)**	
	Missing	**13**	**13 (3%)**	**0**	
Disease Site	**Soft Palate**	**132 (24%)**	**129 (25%)**	**3 (9%)**	**0.01**
	Tongue Base	**90 (17%)**	**88 (17%)**	**2 (6%)**	
	Tonsil	**315 (58%)**	**286 (56%)**	**29 (85%)**	
	Oropharynx, Other	**4 (1%)**	**4 (<1%)**	**0**	
Initial Treatment	Chemoradiation	403 (75%)	377 (75%)	26 (76%)	0.56
	Radiation	89 (17%)	85 (17%)	4 (12%)	
	Surgery	43 (8%)	39 (8%)	4 (12%)	
Risk Factors					
Alcohol	**Yes**	**278 (51%)**	**272 (54%)**	**6 (18%)**	**<0.0001**
Smoke	**Yes**	**448 (83%)**	**441 (87%)**	**7 (21%)**	**<0.0001**
Betel Quid	**Yes**	**349 (65%)**	**345 (68%)**	**4 (12%)**	**<0.0001**
Outcomes (within 5 years)					
Death		274	263	11	
Recurrence		95	91	4	
Neck recurrence		82	79	3	
Metastasis		54	50	4	

p-values derived from t-test (continuous measures) or Chi-square test (categorical) by HPV status, missing values were excluded. TNM classification, according to the 7th AJCC staging edition: "T" (T classification), "N" (N classification), and "Stage" (overall stage). Because all cases were presented with no metastasis (M0), there is no heading for M.

S2 Fig. Kaplan-Meier plots for survival outcomes by gender. Up to 5-year overall survival (OS) and disease-free survival (DFS) outcomes were analyzed within the whole cohort by the Kaplan-Meier method and log-rank test (*p*-values).



S6 Table. Multivariable survival analysis of the whole cohort.

Outcome	Variable	Value	*p*-Value	HR	HR 95% CI	
					Lower	Upper
OS	**HPV**	**HPV+**	**0.0009**	**0.57**	**0.41**	**0.80**
		HPV-	**ref**			
	T-stage	**T0/T1**	**<0.0001**	**0.34**	**0.22**	**0.55**
		T2	**<0.0001**	**0.40**	**0.29**	**0.54**
		T3	**0.001**	**0.58**	**0.42**	**0.80**
		T4	**ref**			
	N-stage	**N0**	**ref**			
		N1	0.90	1.03	0.69	1.54
		N2	0.62	1.08	0.80	1.46
		N3	**0.002**	**1.90**	**1.26**	**2.86**
	Alcohol	**Y**	**<0.0001**	**2.02**	**1.52**	**2.68**
		N	**ref**			
	Smoke	Y	0.11	0.72	0.48	1.08
		N	ref			
	Betel Quid	Y	0.38	0.87	0.63	1.19
		N	ref			
DFS	**HPV**	**HPV+**	**<0.0001**	**0.53**	**0.40**	**0.72**
		HPV-	**ref**			
	T-stage	**T0/T1**	**0.0002**	**0.47**	**0.32**	**0.69**
		T2	**<0.0001**	**0.53**	**0.40**	**0.70**
		T3	**0.04**	**0.72**	**0.53**	**0.98**
		T4	**ref**			
	N-stage	**N0**	**ref**			
		N1	0.93	0.98	0.69	1.41
		N2	0.61	1.07	0.82	1.41
		N3	**0.004**	**1.78**	**1.21**	**2.64**
	Alcohol	**Y**	**<0.0001**	**1.70**	**1.31**	**2.21**
		N	**ref**			
	Smoke	Y	0.20	0.79	0.54	1.14
		N	ref			
	Betel Quid	Y	0.33	0.86	0.64	1.16
		N	ref			

Cox proportional hazard regression analysis of each outcome. OS, overall survival; DFS, disease-free survival. Ref = reference category.

S7 Table. Multivariable survival analysis for alcohol, smoking, and quid within HPV Risk Groups, adjusted for T- and N-stage.

			HPV-positive				HPV-negative			
Outcome	**Variable**	**Value**	***p*-Value**	**HR**	**HR 95% CI**		***p*-Value**	**HR**	**HR 95% CI**	
					Lower	**Upper**			**Lower**	**Upper**
OS	Alcohol	Y	0.08	1.69	0.95	3.03	**0.0004**	**1.72**	**1.28**	**2.31**
		N		ref				**ref**		
	Smoke	Y	0.98	0.99	0.53	1.87	0.99	1.00	0.56	1.79
		N		ref				ref		
	Betel Quid	Y	0.79	0.93	0.52	1.64	0.41	0.87	0.63	1.21
		N		ref				ref		
DFS	Alcohol	Y	0.29	1.33	0.79	2.23	**0.003**	**1.49**	**1.14**	**1.95**
		N		ref				**ref**		
	Smoke	Y	0.26	0.78	0.78	1.20	0.25	0.80	0.54	1.17
		N		ref				ref		
	Betel Quid	Y	0.96	1.01	0.60	1.72	0.29	0.85	0.64	1.14
		N		ref				ref		

Cox proportional hazard regression analysis of each outcome within each HPV status cohort. Behavior variable added individually to model adjusted for T- and N-stage. OS, overall survival; DFS, disease-free survival. Ref = reference category.

S3 Fig. Kaplan-Meier plots for survival outcomes by alcohol, smokeing and betel quid. (A-C) Comparison of prognostic outcomes of alcohol (A), smoking (B), and betel quid (C) between the whole cohort and HPV risk groups. Up to 5-year overall survival (OS, top) and disease-free survival (DFS, bottom) probabilities were analyzed by the Kaplan-Meier method and log-rank test (*p*-values), as displayed for each risk group. HPV-, HPV-negative; HPV+, HPV-positive.




B
Whole cohort
HPV+
HPV-
OS Probability
DFS Probability
Smoke=No
Smoke=Yes
p=0.24
p=0.44
p=0.28
p=0.40
p=0.49
p=0.16
Years
No. at risk:
Smoke=
No 93 68 61 52 47 36 53 43 41 37 32 25 39 24 19 14 14 10
Yes 448 340 273 215 164 137 97 86 73 58 44 40 339 245 192 150 115 93
No 93 51 38 31 27 18 53 34 27 24 21 14 39 16 11 7 6 4
Yes 448 226 160 120 94 62 97 57 47 46 29 22 339 162 107 78 61 36
C
Betel quid=No
Betel quid=Yes
p=0.05
p=0.41
p=0.68
p=0.05
p=0.21
p=0.46
Betel quid=
No 192 149 124 104 86 69 97 83 75 66 53 43 93 64 47 36 31 24
Yes 349 259 210 163 125 104 53 46 39 29 23 22 285 205 164 128 98 79
No 192 106 73 60 51 37 97 62 49 42 35 23 93 42 23 17 15 13
Yes 349 171 125 91 70 43 53 29 25 18 15 13 285 136 95 68 52 27

S4 Fig. HPV-positive OPSCC is associated with increased disease-free survival time in the presence of other risk factors. (A-C) Up to 5-year disease-free survival (DFS) prognostic outcome of HPV within alcohol and smoke+quid risk groups. The smoke+quid group comprises OPSCC cases with both cigarette smoking and/or betel quid chewing. DFS for smoking and betel quid variables were not analyzed individually due to low number of events. (A) Table includes the multivariable hazard probabilities analyzed using Cox survival models and hazard ratio (HR) estimations, which were visualized by forest plots. HPV- is reference. The complete analysis is found in S8 Table. (B-C) Kaplan-Meier survival analysis. Plots represent the DFS probabilities of cases stratified by HPV status within the alcohol (B) and smoke and/or betel quid groups (C). Left, plots showing cases with alcohol or smoke+quid consumption. Right, plots showing cases without exposition to alcohol or smoke+quid. Log-rank analysis was used to compare the survival distributions (log-rank *p*-values are in the plots). HPV-, HPV-negative; HPV+, HPV-positive.



S8 Table. Multivariable disease-free survival analysis by HPV within alcohol, and smoking plus betel quid risk groups (controlled for alcohol, and smoking plus betel quid).

			Alcohol = Yes				Alcohol = No			
Outcome	**Variable**	**Value**	***p*-Value**	**HR**	**HR 95% CI**		***p*-Value**	**HR**	**HR 95% CI**	
					Lower	**Upper**			**Lower**	**Upper**
DFS	HPV	HPV+	**0.01**	**0.62**	**0.43**	**0.89**	**0.02**	**0.60**	**0.39**	**0.92**
		HPV-		**ref**				**ref**		
			Smoke+Quid = Yes				**Smoke+Quid = No**			
Outcome	**Variable**	**Value**	***p*-value**	**HR**	**HR 95% CI**		***p*-value**	**HR**	**HR 95% CI**	
					Lower	**Upper**			**Lower**	**Upper**
DFS	HPV	HPV+	**0.002**	**0.59**	**0.43**	**0.82**	0.11	0.55	0.27	1.13
		HPV-		**ref**				ref		

Cox proportional hazard regression analysis of each outcome in each risk group. HPV variable added individually to model adjusted for T- and N-stage. The "Smoke+Quid" variable includes smoking and/or betel quid events. DFS, disease-free survival. Ref = reference category.